The H2S-releasing naproxen derivative ATB-346 and the slow-release H2S donor GYY4137 reduce intestinal inflammation and restore transit in postoperative ileus by Van Dingenen, Jonas et al.
Frontiers in Pharmacology | www.frontiersin.org 1 February 2019 | Volume 10 | Article 116
ORIGINAL RESEARCH
published: 20 February 2019
doi: 10.3389/fphar.2019.00116
Edited by: 
Gabriella Aviello, 
University of Aberdeen, 
United Kingdom
Reviewed by: 
Jose A. Uranga, 
Universidad Rey Juan Carlos, Spain
Elisabetta Panza, 
University of Naples Federico II, Italy
*Correspondence: 
Romain A. Lefebvre 
romain.lefebvre@ugent.be
Specialty section: 
This article was submitted to 
Gastrointestinal and Hepatic 
Pharmacology, 
a section of the journal 
Frontiers in Pharmacology
Received: 21 November 2018
Accepted: 30 January 2019
Published: 20 February 2019
Citation:
Van Dingenen J, Pieters L, Vral A 
and Lefebvre RA (2019) 
The H2S-Releasing Naproxen 
Derivative ATB-346 and the 
Slow-Release H2S Donor GYY4137 
Reduce Intestinal Inflammation and 
Restore Transit in Postoperative Ileus.
Front. Pharmacol. 10:116.
doi: 10.3389/fphar.2019.00116
The H2S-Releasing Naproxen 
Derivative ATB-346 and the Slow-
Release H2S Donor GYY4137 Reduce 
Intestinal Inflammation and Restore 
Transit in Postoperative Ileus
Jonas Van Dingenen1, Leen Pieters2, Anne Vral2 and Romain A. Lefebvre1*
1 Department of Basic and Applied Medical Sciences, Heymans Institute of Pharmacology, Faculty of Medicine and Health 
Sciences, Ghent University, Ghent, Belgium, 2 Department of Human Structure and Repair, Faculty of Medicine and 
Health Sciences, Ghent University, Ghent, Belgium
Objective: Intestinal inflammation triggers postoperative ileus (POI), commonly seen 
after abdominal surgery and characterized by impaired gastrointestinal transit; when 
prolonged, this leads to increased morbidity. Hydrogen sulfide (H2S) is recognized as 
an important mediator of many (patho)physiological processes, including inflammation, 
and is now investigated for anti-inflammatory application. Therefore, the aim of this 
study was to investigate the effect of the H2S-releasing naproxen derivative ATB-346, 
developed to reduce gastrointestinal injury by naproxen, and the slow-release H2S 
donor GYY4137 on intestinal inflammation and delayed gastrointestinal transit in 
murine POI.
Methods: C57Bl6J mice were fasted for 6 h, anesthetized and after laparotomy, POI 
was induced by compressing the small intestine with two cotton applicators for 5 min 
(intestinal manipulation; IM). GYY4137 (50 mg/kg, intraperitoneally), ATB-346 (16 mg/
kg, intragastrically) or naproxen (10 mg/kg, intragastrically) were administered 1 h 
before IM. At 24 h postoperatively, gastrointestinal transit was assessed via fluorescent 
imaging, and mucosa-free muscularis segments were prepared for later analysis. 
Inflammatory parameters and activity of inducible nitric oxide synthase (iNOS) and 
cyclo-oxygenase (COX)-2 were measured. Histological examination of whole tissue 
sections was done on hematoxylin-eosin stained slides.
Results: Pre-treatment with GYY4137 (geometric center; GC: 7.6 ± 0.5) and ATB-346 
(GC: 8.4 ± 0.3) prevented the delayed transit induced by IM (GC: 3.6 ± 0.5 vs. 9.0 ± 0.4 in 
non-operated controls) while naproxen only partially did (GC: 5.9 ± 0.5; n = 8 for all 
groups). GYY4137 and ATB-346 significantly reduced the IM-induced increase in 
muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1β 
and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced 
and only reached significance for MPO activity and IL-6 levels. All treatments significantly 
reduced the increase in COX-2 activity caused by IM, whereas only GYY4137 significantly 
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INTRODUCTION
Postoperative ileus (POI) refers to the transient impairment 
of gastrointestinal motility, which commonly occurs after 
abdominal surgery. It presents clinically as abdominal 
distension, inability to tolerate an oral diet, absence of 
bowel sounds and lack of flatus and defecation. Normally 
it resolves within 3 days, but when prolonged, nausea and 
vomiting will further contribute to increased morbidity, 
length of hospital stay and increased healthcare costs 
(Boeckxstaens and De Jonge, 2009). In the United States 
alone, the annual socio-economic impact of prolonged POI 
is estimated up to 1.46 billion US$ (Goldstein et  al., 2007). 
POI upon intra-abdominal manipulation is induced by an 
acute neurogenic reaction with activation of inhibitory neural 
pathways and more importantly by a following prolonged 
inflammatory reaction triggered in the muscularis externa. 
Activated resident macrophages in the muscular layer play 
a critical role as they release inflammatory cytokines such 
as interleukin (IL)-6 and chemokines such as monocyte 
chemoattractant protein-1 (MCP-1), resulting in an increased 
endothelial expression of adhesion molecules such as 
intercellular adhesion molecule-1 and recruitment of 
circulatory leukocytes. Nitric oxide and prostaglandins 
released from these inflammatory cells will directly impair 
the smooth muscle contractility causing the delay in 
gastrointestinal transit (Boeckxstaens and De Jonge, 2009; 
Wehner et  al., 2012). Laparoscopic procedures, enhanced 
recovery pathways and pharmacological treatment options 
such as prokinetics and non-steroidal anti-inflammatory 
drugs (NSAIDs) are advised to prevent prolonged POI but 
no full protection is obtained (Person and Wexner, 2006; 
Augestad, 2010; Bragg et al., 2015). Therefore, there is need 
for new treatment options, especially those targeting the 
intestinal inflammation (Van Bree et  al., 2012).
Hydrogen sulfide (H2S), primarily known as a toxic environmental 
gas, is endogenously produced in mammalian tissue from cysteine, 
largely via three enzymes: cystathionine γ-lyase, cystathionine 
β-synthetase and 3-mercaptosulfurtransferase (Rose et  al., 2017). 
H2S biosynthesis has been identified in a variety of mammalian 
tissues including lung, liver, heart and intestine and it has become 
clear that H2S, next to other endogenous gases like nitric oxide 
and carbon monoxide, plays an important role in both physiological 
and pathophysiological processes (Chen et  al., 2007; Olas, 2015). 
Its role in inflammation is possibly one of the more controversial 
areas of the H2S biology as there are a lot of conflicting data 
concerning the pro- and/or anti-inflammatory properties of exogenous 
H2S. For example, administration of sodium hydrosulfide (NaHS), 
an H2S donor, was shown to inhibit aspirin-induced leukocyte 
adherence in mesenteric venules and reduced the leukocyte infiltration 
in an air pouch model in rats (Zanardo et  al., 2006). In contrast, 
pre-treatment of mice with NaHS was shown to significantly enhance 
the lipopolysaccharide (LPS)-induced leukocyte adhesion, neutrophil 
migration and expression of adhesion molecules like P-selectin and 
intercellular adhesion molecule-1 in venular endothelium (Dal-Secco 
et  al., 2008). One reason for the lack of clarity is the reliance on 
NaHS as an H2S donor in many studies; sulfide salts like NaHS, 
dissolved in aqueous solutions, will release large amounts of H2S 
within seconds (Li et al., 2008). Although the precise kinetic profile 
of endogenous H2S release within individual tissues has yet to 
be evaluated, it is likely that the controlled enzymatic H2S synthesis 
occurs at a much slower rate and in lesser amounts. Therefore, 
NaHS may not mimic the biological effects of endogenously produced 
H2S and, depending on the used dosage, may even exert toxic 
effects (Rose et  al., 2015). In contrast to sulfide salts, GYY4137 
[morpholin-4-ium 4 methoxyphenyl(morpholino) phosphinodithioate] 
releases H2S slowly both in vitro and in vivo for several hours, 
better mimicking the time course of naturally produced H2S, making 
this H2S donor more suitable to investigate the effect of exogenous 
H2S (Li et  al., 2008; Lee et  al., 2011). The anti-inflammatory effects 
of GYY4137 have already been shown in a variety of animal models 
including myocardial (Meng et  al., 2015; Karwi et  al., 2016; Qiu 
et al., 2018) and intestinal (Jensen et al., 2018) ischemia/reperfusion 
injury, LPS-induced endotoxemia (Li et al., 2009; Chen et al., 2016), 
atherosclerosis (Liu et  al., 2013; Xie et  al., 2016) and cisplatin-
induced nephrotoxicity (Cao et  al., 2018), whereby GYY4137 was 
able to reduce myeloperoxidase (MPO) activity and the level of 
pro-inflammatory cytokines such as IL-1β, IL-6, tumor necrosis 
factor-α and interferon (IFN)γ.
As mentioned earlier, NSAIDs are already used to treat 
pain and inflammation during prolonged POI allowing to 
spare opioids (Person and Wexner, 2006). However, NSAIDs, 
which suppress synthesis of prostaglandins by inhibiting 
reduced the increase in iNOS activity. Naproxen treatment caused significant histological 
damage of intestinal villi.
Conclusion: The study shows that naproxen partially prevents POI, probably through 
its inhibitory effect on COX-2 activity. Both ATB-346 and GYY4137 were more effective, 
the result with GYY4137 showing that H2S per se can prevent POI.
Keywords: ATB-346, GYY4137, hydrogen sulfide, naproxen, postoperative ileus
Abbreviations: ADHP, 10-acetyl-3,7-dihydroxy-phenoxazine; ANOVA, One-way 
analysis of variance; COX, Cyclo-oxygenase; FD70, Fluorescein-labeled dextran 
(70 kDa); GC, Geometric center; HETAB, Hexadecyl-trimethylammonium bromide; 
H2S, Hydrogen sulfide; IFN, Interferon; i.g., Intragastrically; IL, Interleukin; IM, 
Intestinal manipulation; i.p., Intraperitoneally; MCP-1, Monocyte chemoattractant 
protein-1; MPO, Myeloperoxidase; NaHS, Sodium hydrosulfide; NSAID, Non-steroidal 
anti-inflammatory drug; POI, Postoperative ileus.
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cyclooxygenase (COX), are a major cause of gastric and 
duodenal ulceration and have been shown to also injure more 
distal parts of the small intestine, where the damage is more 
difficult to detect and treat (Wallace et  al., 2011; Takeuchi 
and Satoh, 2015). It has been shown that H2S-releasing NSAIDs 
like ATB-346 [2-(6-methoxy-napthalen-2-yl)-propionic acid 
4-thiocarbamoyl-phenyl ester], being the H2S-releasing derivative 
of naproxen, reduce the NSAID stimulated gastric leukocyte 
adhesion and protect the mucosa from ulceration (Wallace, 
2007; Ekundi-Valentim et  al., 2013). Moreover, released H2S 
will contribute to the overall anti-inflammatory effect of 
ATB-346; multiple studies have demonstrated a superior anti-
inflammatory effect of ATB-346 when compared to naproxen 
as ATB-346 was able to reduce several inflammatory parameters 
like leukocyte infiltration, COX-2 activity and expression 
of  IL-1β and tumor necrosis factor-α more effectively 
(Wallace  et  al., 2010; Campolo et  al., 2013; Dief et  al., 2015; 
Magierowski et  al., 2017).
In the present study, we  investigate the effect of a single 
dose of GYY4137 and ATB-346 on the delay in transit and 
inflammation during POI in mice and compare their effect 
with that of naproxen.
MATERIALS AND METHODS
Materials
GYY4137 (Tocris Bioscience, Bristol, UK) was dissolved in saline 
(6.25 mg/ml) and ATB-346 (2 mg/ml; Axon Medchem, Groningen, 
Netherlands) and naproxen (1.25 mg/ml; Sigma-Aldrich, Diegem, 
Belgium) were suspended in 0.5% (m/v) methocel (methylcellulose, 
Sigma-Aldrich)/H2O. Isoflurane (IsoFlo®, Abbott Laboratories 
Ltd, Maidenhead, Berkshire, UK) was used to anaesthetize the 
mice when inducing POI. Fluorescein-labeled dextran (70  kDa; 
Invitrogen, Merelbeke, Belgium) was used to measure postoperative 
gastrointestinal transit.
Animals
Seven weeks old male C57BL/6J mice were purchased from 
Janvier, Le Genest St-Isle, France and were used between 8 
and 12  weeks of age (22–25  g). Mice were housed in an 
animal care facility with a 12  h light/dark cycle and had 
free access to water and commercially available chow. 
Animal  care and experimental procedures were approved 
by the Ethical Committee for Animal Experiments from the 
Faculty  of  Medicine and Health Sciences at Ghent 
University  (ECD  16–48).
Surgical Procedure
POI was induced by surgical manipulation of the small intestine 
(intestinal manipulation, IM) as previously applied by several 
groups (Kalff et  al., 2000; De Jonge et  al., 2003; Cosyns et  al., 
2015). Mice were anaesthetized with inhaled isoflurane 
(induction, 5%; maintenance, 2%) and the abdomen was opened 
by midline laparotomy. The small intestine was exteriorized 
and then compressed for 5  min along its entire length by 
using sterile moist cotton swabs. The bowel was repositioned 
in the abdominal cavity and the incision was closed by two 
layers of continuous sutures. The total duration of the procedure 
was approximately 20–25  min. After the operation, mice were 
sacrificed at 24  h after induction of POI. The gastrointestinal 
tract from stomach until colon was then isolated. After 
measuring intestinal transit (see Section “Measurement of 
Intestinal Transit”), the gastrointestinal tract was flushed with 
aerated (5% CO2 in O2) ice-cold Krebs solution containing 
1  mM phenylmethylsulfonyl fluoride. The small intestine was 
divided in 6 segments of equal length. Whole tissue sections 
of segment 3 were fixed in formalin for further histological 
examination. The mucosa was removed in the other segments 
using a glass slide and the muscular layer was stored at −80°C 
until further analysis.
Experimental Protocol
Mice were randomly assigned to five experimental groups 
(n  =  8 per group). Group I  served as control (non-treated, 
non-operated). Group II underwent surgical manipulation 
of the small intestine (IM). Group III to V received respectively 
GYY4137 intraperitoneally (i.p., 50  mg/kg), naproxen 
intragastrically (i.g., 10  mg/kg) and ATB-346 i.g. (16  mg/kg) 
at 1 h before the surgical procedure. All animals were deprived 
of food from 6  h before IM but had again access to food 
after IM. At 21  h after surgery, mice were again deprived of 
food to allow measurement of intestinal transit (see Section 
“Measurement of Intestinal Transit”). Mice were sacrificed 
at  24  h after surgery. Figure 1 shows a schematic overview 
of  the protocol.
Measurement of Intestinal Transit
Intestinal transit was measured by evaluating the distribution 
of non-absorbable fluorescein-labeled dextran (70  kDa; FD70) 
along the gastrointestinal tract as previously described (De 
Backer et  al., 2008). 21  h after IM, the mice were deprived 
of food and 1.5 h hereafter a liquid fluorescein-labeled dextran 
meal (200  μl of a 25  mg/ml solution) was gavaged. 1.5  h 
later, i.e. 24  h after surgery, the animals were sacrificed. After 
excision of the gastrointestinal tract, two full-field images (one 
in normal illumination mode and another in fluorescent mode) 
were taken with a CCD camera and subsequently matched 
for calculation of fluorescence distribution along the 
gastrointestinal tract. The fluorescent intensity throughout the 
entire gastrointestinal tract was analyzed and calculated. Data 
were expressed as the percentage of fluorescence intensity per 
segment (stom, stomach; sb, small bowel segments 1–10; caec, 
caecum; col, colon segments 1–2). The geometric center (GC) 
of the fluorescence distribution, which can be  described as 
the center of gravity for the distribution of fluorescein, was 
calculated by the formula: ∑(% FD70 per segment*segment 
number)/100). It can range from 1, if all fluorescein were 
found in the stomach, to 14, if all fluorescein were found in 
the second segment of the colon.
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Biochemical Analyses
MPO Activity
MPO activity in mucosa-free segments of the small intestine 
was measured as an index of neutrophil infiltration, based on 
a previously described protocol (De Jonge et  al., 2003).
Frozen tissue samples were homogenized with a Mikro-
Dismembrator and dissolved in 10 volumes of 50 mM potassium 
phosphate buffer (pH  6.0) containing 0.5% hexadecyl-
trimethylammonium bromide (HETAB). The homogenate was 
sonicated on ice (15 pulses of 0.7 s at full power) and subsequently 
subjected to freeze/thaw. The suspension was centrifuged 
(14,000  g, 20  min, 4°C) and 10  μl of the supernatant was 
added to 200  μl of assay mixture, containing ready-to-use 
3,3′,5,5′-tetramethylbenzidine substrate, 0.5% HETAB, and 
10  mM EDTA (on ice). The optical density was immediately 
read at 620  nm (Biotrak II). The reaction was then allowed 
to proceed for 3  min at 37°C. The reaction was stopped by 
placing the 96-well plate on ice, and the optical density was 
measured again. One unit of MPO activity was defined as the 
amount of enzyme that produces a change in optical density 
of 1.0 per minute at 37°C. Results were normalized to total 
protein content (Pierce BCA Protein Assay Kit) and expressed 
as U/mg protein.
IL-1β, IL-6, IL-10, IFNγ and MCP-1 Protein Levels
Protein expression levels of IL-1β, IL-6, IL-10, IFNγ and MCP-1 in 
mucosa-free segments of the small intestine were assessed by 
a Luminex magnetic bead assay according to the manufacturer’s 
guidelines (Bio-Rad, Temse, Belgium); the samples were processed 
using the BioPlex Pro Reagent Kit (Bio-Rad).
Frozen tissue samples were homogenized in PBS, containing 
protease and phosphatase inhibitors. The homogenate was 
sonicated on ice (5 pulses of 0.7  s) and after centrifugation 
(15,000  rpm, 15  min, 4°C), 50  μl of the supernatant was 
added to the corresponding well of a 96-well plate loaded 
with coupled beats for IL-1β, IL-6, IL-10, IFNγ and MCP-1. 
After placing the plate for 30  min on a shaking platform at 
850  rpm protected from light, wells were washed and 25  μl 
of the mixture of detection antibodies for IL-1β, IL-6, IL-10, 
IFNγ and MCP-1 was added to each well. After placing the 
plate for another 30  min on the shaking platform at 850  rpm 
protected from light, wells were washed and 50 μl of Streptavidin 
Phycoerythrin solution was added to each well. After placing 
the plate for 10  min on the shaking platform at 850  rpm 
protected from light, wells were washed and the beads in 
each well were re-suspended in 125  μl assay buffer. After a 
last incubation step of 30  s, the wells were analyzed for IL-1β, 
IL-6, IL-10, IFNγ and MCP-1 protein concentration using 
Bio-Plex Manager Software (Bio-Rad). Data from tissue samples 
were normalized to the total protein content (Pierce BCA 
Protein Assay Kit).
COX-2 Activity
COX-2 enzyme activity was measured in mucosa-free segments 
by COX activity assay (Cayman Chemical) using arachidonic 
acid as a substrate and 10-acetyl-3,7-dihydroxy-phenoxazine 
(ADHP) as a fluorometric co-substrate. The reaction between 
COX-derived prostaglandin G2 and ADHP produces the highly 
fluorescent compound resorufin, which was measured.
Frozen tissue samples were homogenized with a Mikro-
Dismembrator, dissolved in 5 volumes of 100  mM Tris-HCl 
buffer (pH  7.5), containing protease inhibitors, and centrifuged 
at 10,000  g for 15  min at 4°C. 10  μl of the supernatant was 
transferred to the appropriate well containing 140  μl of 1X 
Assay Buffer (100  mM Tris-HCl, pH  8.0), 10  μl of Heme in 
DMSO and 10  μl of the COX-1 inhibitor SC-560 (66  μM). 
After an incubation period of 5  min, 10  μl of ADHP Assay 
Reagent was added to each well. Administration of 10  μl of 
a 2  mM arachidonic acid solution to each well initiated the 
reaction; 1  min later the plate was measured using a 
spectrofluorometer (excitation wavelength: 530–540 nm, emission 
wavelength: 585–595  nm; Victor Wallac, PerkinElmer Life and 
Analytical Sciences). Background values were measured by not 
adding 10  μl of the arachidonic acid solution to the assigned 
wells and were deducted from the corresponding sample values. 
Results were normalized to total protein content (Pierce BCA 
FIGURE 1 | Schematic overview of experimental protocol. Mice were deprived of food from 6 h before intestinal manipulation (IM) and given GYY4137, ATB-346 or 
naproxen 1 h before IM. When mice recovered from surgery, they had again access to food. Mice were deprived of food at 21 h after IM and received 200 μl of 
fluorescein-labeled dextran (FD70) at 22.5 h after IM. 1.5 h later, mice were sacrificed followed by measurement of the gastrointestinal transit and collection of tissue 
samples of the small intestine.
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Protein Assay Kit) and COX-2 activity was expressed as % of 
mean fluorescence in tissue from non-manipulated control mice.
iNOS Activity
Inducible NO synthase (iNOS) enzyme activity in intestinal 
muscularis samples was assayed by measuring the conversion 
of [3H]-arginine to [3H]-citrulline by use of a NOS activity 
assay (Cayman Chemical), according to the manufacturer’s 
protocol. The assay was conducted in calcium-free conditions 
to measure only iNOS.
Frozen tissue samples were homogenized with a Mikro-
Dismembrator, dissolved in five volumes of 1X Homogenization 
Buffer and centrifuged at 10,000  g for 15  min at 4°C. 10  μl 
of the supernatant was added to 40  μl reaction mix (22.72  μl 
of Reaction Buffer [50  mM Tris-HCl (pH  7.4), 6  μM 
tetrahydrobiopterin, 2  μM flavin adenine dinucleotide, 2  μM 
flavin adenine mononucleotide], 4.55  μl of 10  mM NADPH 
(prepared in 10  mM Tris-HCl), 0.90  μl of [3H]-arginine 
(1 μCI/μl), 4.55  μl 8  mM  Mg acetate, 3.64  μl calmodulin and 
3.64  μl ddH2O). The reaction samples were incubated for 1  h 
at room temperature, and the reaction was stopped by adding 
400  μl of Stop Buffer to the reaction sample. 100  μl of the 
equilibrated resin was added into each reaction sample and 
the reaction samples were then transferred in the provided 
spin cups, which were centrifuged for 30 s in a microcentrifuge 
at full speed. The eluate was then transferred to scintillation 
vials, and, after adding 2 ml scintillation solution (Ultima Gold, 
Canberra Packard, USA) to each vial, the radioactivity was 
quantified in a liquid scintillation counter (Packard Tri-Carb 
2,100 TR, Canberra Packard, USA). Results were normalized 
to total protein content (Pierce BCA Protein Assay Kit) and 
iNOS activity was expressed as % of [3H]-citrulline in tissue 
from non-manipulated control mice.
Intestinal Histological Evaluation
Intestinal samples were fixed in formalin, dehydrated in a 
graded ethanol series and embedded in paraffin. Tissue sections 
of 5  μM were cut with a microtome and then stained with 
hematoxylin-eosin. Jonas Van Dingenen and Leen Pieters 
independently scored the slides to evaluate intestinal mucosal 
damage using the Chiu score (Chiu et  al., 1970): grade 0, 
normal mucosa villi; grade 1, development of sub-epithelial 
Gruenhagen’s space at the apex of the villi; grade 2, extension 
of the sub-epithelial space with moderate epithelial lifting; grade 
3, massive epithelial lifting, possibly with a few denuded villi; 
grade 4, denuded villi with lamina propria and exposed capillaries; 
and grade 5, disintegration of the lamina propria, ulceration 
and hemorrhage. For each sample, 100 villi were scored by 
both evaluators and the mean score per sample was calculated. 
Good correlation between the scores of the two evaluators is 
illustrated by a Pearson’s r-value of 0.8324.
Statistical Analysis
Data are given as mean  ±  s.e.m. as indicated; n refers to 
tissues obtained from different animals. The results were compared 
by one-way analysis of variance (ANOVA), followed by Bonferroni 
multiple comparison t-test for all manipulated groups vs. the 
non-operated control group and for the treated manipulated 
groups vs. the non-treated manipulated group. Results were 
considered different from a p less than 0.05 on (GraphPad 
version 5.03, San Diego, CA, USA). The Grubbs’ test was used 
to determine significant outliers (p  <  0.05), that were excluded 
for further statistical analysis (Grubbs, 1969). The Pearson 
correlation test was used to investigate the correlation between 
the scores of the two evaluators performing the intestinal 
histological evaluation.
RESULTS
Effect of GYY4137, Naproxen and ATB-346 
on Manipulation-Induced Intestinal 
Dysmotility
In non-manipulated control mice, fluorescein-labeled dextran had 
mainly moved to the distal part of the small bowel (Figure 2A). 
In mice that underwent intestinal manipulation, fluorescein-labeled 
dextran was mostly present in the proximal part of the small 
bowel, pointing out a delay in transit (Figure 2B), which was 
confirmed by a significant reduction in GC (Figure 2F). 
Pre-treatment with 50 mg/kg GYY4137 i.p. or 16 mg/kg ATB-346 
i.g. reduced the delay in transit caused by IM, as indicated 
by the shift of fluorescein-labeled dextran to the distal part of 
the small bowel (Figures 2C–E); the GC was significantly increased 
vs. that in untreated manipulated animals and no longer 
significantly different from that in non-manipulated control mice 
(Figure 2F). Pre-treatment with naproxen did not completely 
prevent the delay in transit caused by IM as the GC-value was 
still significantly different from that in non-manipulated control 
mice (Figure 2F).
Effect of GYY4137, Naproxen and ATB-346 
on Manipulation-Induced Inflammation
The leukocyte infiltration into the muscularis, measured as 
MPO activity, was increased 24  h after IM. This IM-induced 
accumulation of leukocytes in the muscular layer was significantly 
reduced when mice were pre-treated with 50  mg/kg GYY4137 
i.p., 10 mg/kg naproxen i.g. or 16 mg/kg ATB-346 i.g. (Figure 3A). 
However, the MPO activity in the naproxen treated group 
was still significantly increased compared to the non-manipulated 
control group.
As shown in Figures 3B–D, surgical manipulation of the 
small intestine markedly increased IL-1β, MCP-1 and IL-6 protein 
expression in the intestinal muscular layer at 24  h after IM. 
Pre-treatment with all three compounds resulted in a significant 
reduction of the elevated IL-6 levels but the level of IL-6  in the 
group treated with naproxen remained significantly different from 
that in non-manipulated control animals (Figure 3D). Only 
GYY4137 and ATB-346 were able to significantly reduce the 
increase in IL-1β and MCP-1 levels caused by IM (Figures 3B,C). 
No significant increase in protein expression of IL-10 and IFNγ 
was observed in the muscularis of manipulated mice with the 
Luminex magnetic bead assay (Figures 3E,F).
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Effect of GYY4137, Naproxen and ATB-346 
on Intestinal iNOS and COX-2 Activity
Surgical manipulation of the small intestine caused a significant 
increase in iNOS enzyme activity in the muscularis. Only 
GYY4137 significantly reduced this increase in iNOS activity. 
Treatment with ATB-346 also tended to reduce the elevated 
iNOS activity, but this effect was not significant (Figure 4A). 
Surgery also caused a pronounced increase in COX-2 activity. 
All three compounds were able to significantly reduce the 
increased COX-2 activity caused by IM (Figure 4B).
Effect of GYY4137, Naproxen and ATB-346 
on Morphology of Intestinal Villi
No injury was seen in the non-manipulated control group, which 
demonstrated normal mucosal villi (Figure 5A). However, in 
the non-treated (Figure 5B) and GYY4137 treated (Figure 5C) 
manipulated mice, development of sub-epithelial Gruenhagen’s 
space in the tip of the villi was observed although the increase 
in Chiu score did not reach significance. The intestinal structure 
was damaged most severely in the naproxen treated IM group 
(Figure 5D), regularly showing moderate to massive epithelial 
lifting down the sides of the villi leading to a significant increase 
in Chiu score. Compared to the naproxen treated IM group, 
villi were less damaged when animals were treated with ATB-346 
(Figure 5E), showing Gruenhagen’s space at the apex of the 
villi and moderate epithelial lifting.
DISCUSSION
Hydrogen sulfide therapy has attracted significant attention 
as a potent biological mediator. Although its benefits have 
been appreciated in different gastrointestinal disease models 
like colitis (Fiorucci et  al., 2007; Chen and Liu, 2016) and 
intestinal ischemia/reperfusion injury (Henderson et al., 2010; 
Jensen et  al., 2018), its potential effect on POI has not 
yet  been investigated. POI is a serious complication seen 
after  abdominal surgery, leading to impairment of the 
gastrointestinal transit that traditionally was thought to result 
from neuronal dysfunction. Presently, it is clear that the 
immune response in the intestinal muscular layer upon 
abdominal surgery, characterized by the activation of resident 
macrophages and upregulation of inflammatory cytokines, 
adhesion molecules and chemokines, is the main mechanism 
of POI (Boeckxstaens and de Jonge, 2009; Van Bree et  al., 
2012; Bragg et  al., 2015). Many of the data leading to the 
pathophysiological explanation of POI were obtained in the 
A
B
C
D
E
F
FIGURE 2 | Influence of GYY4137, naproxen and ATB-346 on the delay in gastrointestinal transit caused by intestinal manipulation. Transit histograms (A–E) and 
geometric center (F) for the distribution of fluorescein-labeled dextran (70 kDa) along the gastrointestinal tract (stom, stomach; sb, small bowel segments; caec, 
caecum; col, colon segments), measured 24 h after intestinal manipulation (IM). Data represent the means ± S.E.M. of n = 8. ***p < 0.001 for comparison with  
non-manipulated (NM) control mice; °p < 0.05, °°°p < 0.001 for comparison with non-treated IM mice: one-way ANOVA followed by a Bonferroni multiple 
comparison test.
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murine model of POI with manipulation of the small intestine. 
Throughout the years, this model yielded consistent results 
for transit and inflammation in our and other laboratories 
(Moore et  al., 2003; Nakao et  al., 2006; De Backer et  al., 
2009; Engel et  al., 2010; Snoek et  al., 2012; Cosyns et  al., 
2015). Also in the present study an inflammatory response 
is observed after manipulation of the murine small intestine, 
as shown by the increased leukocyte infiltration and elevated 
protein levels of the pro-inflammatory cytokines IL-6 and 
IL-1β and the chemokine MCP-1  in the intestinal muscularis 
externa at 24  h after induction of POI. Although previous 
reports (De Backer et  al., 2009; Engel et  al., 2010) show 
elevated IL-10 protein and IFNγ mRNA levels at 24  h after 
IM, we  could not measure a significant increase in protein 
expression for these cytokines with the Luminex magnetic 
bead assay used in this study.
GYY4137 is an H2S-releasing molecule that was shown 
to have a pronounced anti-inflammatory effect in rodent 
models of myocardial (Qiu et al., 2018) and intestinal (Jensen 
et  al., 2018) ischemia/reperfusion injury, endotoxemia (Chen 
et  al., 2016) and atherosclerosis (Liu et  al., 2013). The usual 
dose applied is 50  mg/kg by i.p. route (Liu et  al., 2013; 
Chen et  al., 2016; Jensen et  al., 2018; Qiu et  al., 2018). I.g. 
administration of GYY4137 has to be  avoided since the 
release of H2S from GYY4137 will be  enhanced under acidic 
conditions (Li et  al., 2008), possibly leading to toxic H2S 
levels as seen with fast-release H2S donors such as NaHS. 
H2S-releasing naproxen ATB-346 showed beneficial anti-
inflammatory effects in rodent models of colorectal cancer 
(Elsheikh et  al., 2014), melanoma (De Cicco et  al., 2016), 
zymosan-induced arthritis (Dief et  al., 2015), spinal cord 
injury (Campolo et al., 2013) and carrageenan-induced synovitis 
A B
C D
E F
FIGURE 3 | Influence of GYY4137, naproxen and ATB-346 on intestinal manipulation induced inflammation. Leukocyte infiltration ((A); myeloperoxidase activity, 
MPO) and IL-1β (B), MCP-1 (C), IL-6 (D), IFNγ (E) and IL-10 (F) protein levels in the muscular layer, measured 24 h after intestinal manipulation (IM). Data represent 
the means ± S.E.M. of n = 7–8. *p < 0.05, **p < 0.01, ***p < 0.001 for comparison with non-manipulated (NM) control mice; °p < 0.05, °°p < 0.01, °°°p < 0.001 
for comparison with non-treated IM mice: one-way ANOVA followed by a Bonferroni multiple comparison test.
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(Ekundi-Valentim et  al., 2013); the usual dose is 16  mg/kg 
by i.g. route (Ekundi-Valentim et  al., 2013; Elsheikh et  al., 
2014; Dief et  al., 2015). The studied route of administration 
for ATB-346 in rodents is indeed the i.g. one, as the compound 
is developed to improve the efficacy and decrease the side 
effects of the NSAID naproxen, used perorally in clinical 
practice. As neither GYY4137 nor ATB-346 has been tested 
before for POI, this was done in the actual study. I.g. naproxen 
was studied in comparison with ATB-346; the dose used 
(10 mg/kg) is the molar equivalent of the amount of naproxen 
contained within 16  mg/kg ATB-346 and has already been 
shown to exert anti-inflammatory effects in a rat model of 
carrageenan-induced synovitis (Ekundi-Valentim et al., 2013).
In the present study we show that both GYY4137 and ATB-346 
were able to completely reverse the delay in gastrointestinal transit 
seen after IM, whereas naproxen was only able to partially restore 
the delayed transit. The findings for the NSAID naproxen are 
similar to previous work, in which the authors show the beneficial 
effects of pre-treatment with the non-selective COX inhibitors 
indomethacin and ketorolac and the selective COX-2 inhibitor 
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-
2(5H)-furan on the impaired transit in a rat model of POI (De 
Winter et al., 1998; Schwarz et al., 2001). Treatment with GYY4137 
A
B
FIGURE 4 | Influence of GYY4137, naproxen and ATB-346 on intestinal iNOS 
and COX-2 activity. iNOS (A) and COX-2 (B) activity in the muscular layer, 
measured 24 h after intestinal manipulation (IM). Data represent the means ± 
S.E.M. of n = 8. *p < 0.05, ***p < 0.001 for comparison with non-manipulated 
(NM) control mice; °p < 0.05, °°p < 0.01, °°°p < 0.001 for comparison with 
non-treated IM mice: one-way ANOVA followed by a Bonferroni multiple 
comparison test.
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FIGURE 5 | Influence of GYY4137, naproxen and ATB-346 on morphology of 
intestinal villi. Histological analysis and Chiu score (CS;A–E) of small intestinal 
mucosa following hematoxylin-eosin staining, analyzed 24 h after intestinal 
manipulation (IM). Asterisks (*) mark the development of sub-epithelial 
Gruenhagen’s space at villus apex; arrows (→) indicate further epithelial lifting 
down the sides of the villi and the number signs (#) mark massive epithelial 
lifting. Data represent the means ± S.E.M. of n = 4. **p < 0.01 for comparison 
with non-manipulated (NM) control mice: one-way ANOVA followed by a 
Bonferroni multiple comparison test.
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and ATB-346 was also found to reduce the IM-induced 
inflammatory response, as evidenced by a marked reduction of 
the inflammatory mediators IL-1β, IL-6 and MCP-1 and leukocyte 
infiltration; whereas the reduction caused by naproxen only 
reached significance for IL-6 protein levels and leukocyte infiltration. 
These data are consistent with previous evidence showing that 
the H2S-releasing moiety of ATB-346 adds complimentary anti-
inflammatory effects to the COX inhibiting effect of naproxen 
(Wallace et  al., 2010; Campolo et  al., 2013; Dief et  al., 2015; 
Magierowski et  al., 2017). The functional importance of the 
kinetically active substances NO and prostaglandins, that directly 
inhibit smooth muscle contractility, in the pathogenesis of POI 
has been demonstrated in earlier studies (Kalff et  al., 2000; 
Schwarz et  al., 2001). Therefore, we  further investigated whether 
GYY4137, naproxen or ATB-346 could alter iNOS and COX-2 
enzyme activity levels. Only GYY4137 was able to significantly 
reduce both the increased iNOS and COX-2 activity. Similarly, 
in an in vitro study in human synoviocytes and articular 
chondrocytes GYY4137 was able to dose-dependently reduce the 
LPS-induced increase in both iNOS and COX-2 expression and 
activity (Li et  al., 2013). ATB-346 and naproxen did only cause 
a significant reduction in COX-2 activity, although ATB-346 
tended to reduce iNOS activity. These findings are in line with 
the study of Campolo et al. in which ATB-346, but not naproxen, 
was able to attenuate iNOS expression in a murine model of 
spinal cord injury; it has to be  noted that naproxen did also 
not affect COX-2 expression in this model (Campolo et al., 2013). 
However, the same research group also reported that in a model 
of traumatic brain injury in mice, administration of both ATB-346 
and naproxen led to a significant reduction of COX-2 and iNOS 
expression (Campolo et  al., 2014). The absence of any effect 
with naproxen on iNOS activity in the actual study might contribute 
to the less pronounced effect of naproxen on retarded transit.
As mentioned earlier, NSAIDs are a major cause of gastric 
and duodenal ulceration and have been shown to also injure 
more distal parts of the small intestine. The protective effect of 
H2S-releasing NSAIDs like ATB-346 on gastric and intestinal 
lesions has been well described in the literature and a double-
blind, controlled clinical study to compare the gastrointestinal 
safety of ATB-346 vs. naproxen in healthy subjects is ongoing 
(ClinicalTrials.gov1; Wallace, 2007; Wallace et al., 2010; Magierowski 
et  al., 2017). In this study intestinal manipulation per se tended 
to induce moderate mucosal damage although not reaching 
significance; a similar Chiu score was seen in manipulated mice 
pretreated with GYY4137. In manipulated mice, pretreated with 
naproxen, a significant increase in Chiu score was seen, confirming 
the well-known intestinal mucosal injury by NSAIDs. However 
in manipulated mice pretreated with ATB-346, the Chiu score 
was similar to that in non-treated manipulated mice showing 
that the H2S-release from this molecule was able to counteract 
mucosal injury of the naproxen moiety.
Follow-up studies can be performed to unravel the underlying 
mechanisms by which these H2S-releasing compounds exert their 
beneficial effects in the murine model of POI. The most frequently 
described mechanisms by which exogenous H2S exerts its anti-
inflammatory effect are inhibition of the pro-inflammatory nuclear 
transcription factor-κB (Oh et  al., 2006; Li et  al., 2013; Chen 
and Liu, 2016), activation of the anti-oxidant nuclear factor 
erythroid 2–related factor 2 (Shimada et  al., 2015; Xie et  al., 
2016; Qiu et  al., 2018) and inhibition of the mitogen-activated 
protein kinase signaling pathways like p38 and extracellular signal-
regulated kinase 1/2 (Hu et al., 2007; Xu et al., 2013). Furthermore, 
it can be  investigated whether the endogenous H2S pathway is 
upregulated during POI as a protective mechanism, whereby 
exogenous H2S donors then strengthen this reaction; enhanced 
H2S synthesis with increased expression of H2S synthetizing 
enzymes at sites of mucosal ulceration was indeed demonstrated 
in rat colitis (Wallace et  al., 2009; Flannigan et  al., 2013).
This study demonstrates that pre-treatment with GYY4137, 
ATB-346 or naproxen reduces the impaired transit and suppresses 
the IM-induced inflammatory response in the muscularis seen 
during POI in mice, with naproxen being the least effective 
compound. Furthermore, the intestinal mucosal damage with 
naproxen alone was prevented by administering it as a H2S-releasing 
compound. The data suggest that delivery of H2S may represent 
a new pharmacological approach to prevent POI or to improve 
the effect of NSAIDs in POI. NSAIDs are indeed already studied 
for postoperative ileus with some improvement of time to gut 
recovery (Milne et al., 2018). The current data suggest that ATB-346 
is preferable over naproxen per se for application in POI. The 
step to a clinical trial with ATB-346 to prevent POI in patients 
undergoing colorectal surgery seems easily feasible as safety of 
ATB-346 was already shown in a phase 1 study in healthy subjects 
and a phase 2 clinical trial demonstrated pain relief of ATB-346 in 
patients with osteoarthritis; in both studies whole blood COX 
activity was profoundly suppressed (Wallace et  al., 2018).
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